Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $180 from $150 and keeps a Buy rating on the shares. The firm’s discussion with 6 doctors who treat ADA – Alzheimer’s disease agitation – indicates that they unanimously viewed AXS-05’s totality of evidence as supportive of approval with front-line use ahead of brexpiprazole, the analyst tells investors in a research note. Truist also cites the comfort with safety profile of Auvelity – AXS-05 – from experiences in MDD – major depressive disorder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics reports Q4 preliminary Auvelity product sales $92.6M
- Axsome Therapeutics price target raised to $180 from $150 at Truist
- Axsome Therapeutics price target raised to $140 from $138 at RBC Capital
- Top 3 Trending Stocks, According to Analysts – 1/2/2025
- Axsome Therapeutics price target lowered to $122 from $124 at Mizuho